Neuroscience
From TheStreet.com:
[ ... Read the full report ... ]
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Alzheimer Disease: Dimebon Results, Part Ii
From The New York Times: Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing...
- Alzheimer Disease: Dimebon Results
A press release from earlier today by Pfizer: Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program [snip] "About the CONNECTION Study "CONNECTION is a Phase 3, multi-national,...
- Business World: Acadia Pharm, Acp-103, & Parkinson Disease
From an AP report posted at Yahoo!: Acadia Pharma Says Drug Study Encouraging Wednesday June 22, 7:44 pm ET Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc....
- Forthcoming Meeting: Exanta And Stroke Prevention
Reuters reports that the FDA will be holding a meeting tomorrow to discuss Exanta and its use as an anti-stroke medication. Here is the text of the FDA announcement about this meeting: FDA Announcement and the text of the FDA Briefing Note: FDA Briefing...
Neuroscience
Business World: AstraZeneca, Renovis - Cerovive (NXY-059) in Stroke Treatment
From TheStreet.com:
AstraZeneca's Results Boost Tiny Renovis
By Robert Steyer
TheStreet.com Staff Reporter
5/4/2005 1:03 PM EDT
AstraZeneca (AZN :NYSE - commentary -research ) reported mixed results for a late-stage clinical trial of an experimental drug for treating stroke but said it hopes to submit the product for regulatory review during the second half of 2006.
At the same time, the shares of another company involved in the product's development were nearly doubling in heavy trading Wednesday.
The clinical trial involved Cerovive, one of the few AstraZeneca drugs in late-stage clinical development. According to preliminary results, patients taking Cerovive demonstrated statistically significant improvements compared with patients taking a placebo, according to one measurement. But when applying another standard for testing stroke patients, researchers found no significant difference between the two groups.
[ ... Read the full report ... ]
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Alzheimer Disease: Dimebon Results, Part Ii
From The New York Times: Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing...
- Alzheimer Disease: Dimebon Results
A press release from earlier today by Pfizer: Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program [snip] "About the CONNECTION Study "CONNECTION is a Phase 3, multi-national,...
- Business World: Acadia Pharm, Acp-103, & Parkinson Disease
From an AP report posted at Yahoo!: Acadia Pharma Says Drug Study Encouraging Wednesday June 22, 7:44 pm ET Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc....
- Forthcoming Meeting: Exanta And Stroke Prevention
Reuters reports that the FDA will be holding a meeting tomorrow to discuss Exanta and its use as an anti-stroke medication. Here is the text of the FDA announcement about this meeting: FDA Announcement and the text of the FDA Briefing Note: FDA Briefing...